One04 Therapeutics to present late-breaking interim Phase 1 results for CPV-104 in C3 glomerulopathy at ASN Kidney Week followed by Virtual KOL Event

One04 Therapeutics said positive interim Phase 1 data for CPV-104 in patients with C3 glomerulopathy were accepted for a late-breaking poster at ASN Kidney Week. The multiple-ascending-dose analysis covers the first two patient cohorts; the study has three cohorts totaling 18 patients, with dosing in the highest-dose cohort ongoing. In the separate single-ascending-dose arm, 21 healthy volunteers received treatment across four cohorts, with no dose-limiting toxicities or treatment-related serious adverse events observed; the company also reported early signals of clinical activity without providing numerical efficacy results.

Analysis

The value inflection is not the safety update; it is whether patient data show target engagement and a credible link to renal benefit. Tolerability in healthy volunteers offers limited de-risking of repeated dosing in C3G, while interim observations in the first patient cohorts are especially vulnerable to small-sample and duration effects. Treat “early activity” as hypothesis-generating until the poster discloses biomarkers, dose-response, exposure, and any proteinuria or kidney-function trends.

Mechanistically, restoring Factor H regulation could offer a differentiated approach from complement inhibitors that block selected pathway components, and could ultimately complement existing treatment. But differentiation only matters if delivery, durability, and clinical outcomes justify the added treatment burden; the release provides no comparative or commercial evidence. The retinal-disease ambition is optionality, not near-term value: it expands the addressable story without de-risking that program.

The October 22 poster and October 26 KOL discussion are near-term information catalysts, not necessarily investable catalysts: One04 is private and no listed security is identified in the supplied data. A stronger signal would require interpretable dose/exposure relationships and concordant patient biomarkers; absent that, optimism risks outrunning evidence. Over 6–18 months, watch for completion of dose escalation, controlled efficacy design, durability, and financing or partnering terms. Failure to show reproducible pharmacodynamic activity, dose-limiting safety issues at higher exposure, or a prolonged path to controlled testing would reverse the thesis.

Key Decisions for Investors

• No direct position is actionable from the supplied information: One04 is private and no ticker or valuation is provided. Do not translate a promotional interim update into a public-biotech basket trade.
• Use the October 22 poster as a diligence trigger: verify cohort sizes actually analyzed, dose/exposure data, pharmacodynamic markers, adverse events, and whether claimed activity is objective and consistent across patients. If those details are absent, treat the KOL event as narrative rather than evidence.
• Keep existing complement-therapy exposures sized to their own clinical and commercial evidence; CPV-104 is a prospective competitive or combination threat, not yet grounds to short incumbent developers. Reassess only if patient data establish meaningful differentiation and a plausible development path.
• Falsifiers to monitor over the next 1–3 months and subsequent trial updates: safety deterioration in the highest-dose cohort, no dose-related biological effect, lack of reproducible patient-level activity, or a development plan that delays controlled efficacy testing. Positive safety alone would not invalidate these concerns.